Instagram Outage Disrupts Thousands of U.S. Users 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
COLUMBUS, Ohio, Aug. 30, 2016 -- Cleobrothers & Co., Inc. announced that it has recently opened a sales and marketing office in Salvador, Bahia, Brazil as part of its global expansion plan for promoting and distributing pharmaceuticals and hi-tech medical devices in South America, Asia, Africa and the Middle East.
|
|||||
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/dcf12437-65fb-4d2f-a34d-6246da1f7ec6
According to Mr. Innocent Nweze, CEO of Cleobrothers and Co. Inc., “With a population exceeding 200 million people, Brazil provides tremendous potential for launching our brand of over-the-counter medications to retail and medical markets.”
The company currently has a portfolio of over-the-counter (OTC) cold relief and decongestant medications and over 80 Specialty Dermatology/Personal Skin Care Products that are specially formulated for tropical climates.
In addition, Cleobrothers offers a pipeline of two first-in-class technologies -- a 24/7 proprietary Pregnancy Monitoring device and a new Combination Pharmaceutical for management of Type-2 Diabetes. Both technologies are currently in clinical trials with product launches planned for the first quarter of 2017.
The new office will be located at Av. Tancredo Neves, 450-15° andar, 16th Floor, Caminho das Árvores Salvador, BA 41819-900, Brazil. Phone: +55 (71) 3340-0600.
“Having access to U.S. manufactured and FDA approved medications adds a strong competitive advantage to our sales and marketing efforts in Brazil,” Mr. Nweze added.
The Brazilian office opening comes on the heels of the company’s recent announcement of a joint venture agreement with PGC Solutions, Ltd. to distribute, market and promote Cleobrothers branded products in Nigeria.
Cleobrothers & Co., Inc. is a Columbus based biotechnology company focused on researching and developing medical and healthcare innovations that are dedicated to helping people worldwide live better lives.
For more information about Cleobrothers and Co., Inc. visit www.cleobrothers.com
(Office Photo attached)
Contact: Innocent Nweze email: [email protected] Phone: 614.934.1367
